.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
McKinsey
Cipla
Argus Health
UBS
Mallinckrodt
Covington
Julphar
Cantor Fitzgerald
Chubb

Generated: June 26, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,093,298

« Back to Dashboard

Which drugs does patent 8,093,298 protect, and when does it expire?


Patent 8,093,298 protects COLCRYS and is included in one NDA. There has been one Paragraph IV challenge on Colcrys.

Summary for Patent: 8,093,298

Title:Methods for concomitant administration of colchicine and macrolide antibiotics
Abstract: Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.
Inventor(s): Davis; Matthew W. (Erwinna, PA)
Assignee: Mutual Pharmaceutical Company, Inc. (Philadelphia, PA)
Application Number:13/110,087
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Takeda Pharms Usa
COLCRYS
colchicine
TABLET;ORAL022352-001Jul 29, 2009RXYesYes8,093,298► Subscribe METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,093,298

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,093,296Methods for concomitant administration of colchicine and macrolide antibiotics► Subscribe
7,601,758Methods for concomitant administration of colchicine and macrolide antibiotics in the treatment of gout flares► Subscribe
7,935,731Methods for concomitant administration of colchicine and macrolide antibiotics► Subscribe
8,097,655Methods for concomitant administration of colchicine and macrolide antibiotics► Subscribe
7,619,004Methods for concomitant administration of colchicine and macrolide antibiotics► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Argus Health
Fish and Richardson
Julphar
Medtronic
Farmers Insurance
Deloitte
Covington
Chinese Patent Office
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot